Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Price:
0.25 USD
66.67%
Updated:
May 17, 2024
Sonoma Pharmaceuticals Inc
Additional Paid In Capital
|
Sonoma Pharmaceuticals Inc
Additional Paid In Capital Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Additional Paid In Capital
$202.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Additional Paid In Capital
$45.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
85%
|
CAGR 10-Years
41%
|
|
|
Pfizer Inc
NYSE:PFE
|
Additional Paid In Capital
$92.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Additional Paid In Capital
$44.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Additional Paid In Capital
$7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
See Also
What is Sonoma Pharmaceuticals Inc's Additional Paid In Capital?
Additional Paid In Capital
202.8m
USD
202.8m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Additional Paid In Capital amounts to 202.8m USD.
What is Sonoma Pharmaceuticals Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
3%
3%
Over the last year, the Additional Paid In Capital growth was 2%. The average annual Additional Paid In Capital growth rates for Sonoma Pharmaceuticals Inc have been 2% over the past three years , 2% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet
